CYTK Price Prediction Next Week
Analysis and Insights
News and Event Impact:
Cytokinetics (CYTK) has received positive news with Morgan Stanley initiating coverage with an Overweight rating and a $67 price target, highlighting the potential of aficamten's adoption following the MAPLE-HCM study. The company has submitted a 120-day safety update to the FDA ahead of the September 26 PDUFA date and plans a mid-cycle meeting in March, incorporating additional safety data from the FOREST-HCM trial. These developments are expected to positively impact the stock price.
Technical Indicators:
- RSI: The RSI values (36.31 for RSI_6, 41.65 for RSI_12, and 42.36 for RSI_14) indicate the stock is oversold, suggesting a potential rebound.
- Stochastic Oscillator: The Stochastic K (22.17) and D (24.83) lines are in the oversold zone, indicating a possible bullish reversal.
- MACD: The MACD (-0.90) and MACD Histogram (-0.58) are negative, showing bearish momentum, but the narrowing histogram suggests weakening bearish pressure.
- Moving Averages: The stock is below the 5-day (43.43), 10-day (45.23), and 20-day (45.10) SMAs, indicating bearish momentum.
- Bollinger Bands: The stock is near the lower Bollinger Band (36.23), confirming oversold conditions.
Fibonacci Levels:
The Fibonacci levels show a pivot at 46.04, with resistance at 49.50 and support at 42.58. The current price (43.38) is near the lower end, suggesting a potential bounce.
Conclusion:
Given the oversold conditions and positive news, CYTK is likely to see a short-term rebound. The stock may test the lower Fibonacci support before rising.
Predicted Price for Next Trading Week: $44.50
Recommendation: Buy
CYTK Similar Chart Price Prediction
The price of CYTK is predicted to go up -10.32%, based on the high correlation periods with RZB. The similarity of these two price pattern on the periods is 94.4%.
CYTK
RZB
Down: -10.32%Similarity: 94.4%
CYTK Revenue Forecast
CYTK EPS Forecast
CYTK FAQs
What is CYTK revenue forecast for next quarter？
CYTK Analyst's Forecast
Jeffrey Hung
Morgan Stanley
Hold → Buy
2025-02-13
Price Target
$70 → $67
Upside
+60.98%
Morgan Stanley analyst Jeffrey Hung upgraded Cytokinetics (CYTK) to Overweight from Equal Weight with a price target of $67, down from $70. The firm believes investor concerns are now better understood, and the stock's risk/reward is skewed to the upside. After Bristol Myers (BMY) announced on its Q4 call that it has an FDA action date in April for easing the risk evaluation and mitigation strategies echo monitoring requirements in the U.S., the shares declined over 15% to 52-week lows. This has been driven by investor concerns that the REMS for aficamten may ultimately be similar to that for Camzyos, even if different than the current program for Bristol's drug, contends Morgan Stanley. The firm now sees "multiple sources for upside" over the next 12 months for shares of Cytokinetics.
Joseph Pantginis
HC Wainwright & Co.
Strong Buy
2025-01-22
Price Target
$120
Upside
+156.3%
James Condulis
Stifel
Strong Buy
2025-01-22
Price Target
$80
Upside
+70.87%
